Last reviewed · How we verify

ALKS 9072 — Competitive Intelligence Brief

ALKS 9072 (ALKS 9072) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Abuse-deterrent opioid analgesic. Area: Pain Management.

phase 3 Abuse-deterrent opioid analgesic Mu opioid receptor (with opioid antagonist component) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

ALKS 9072 (ALKS 9072) — Alkermes, Inc.. ALKS 9072 is a mu opioid receptor agonist combined with an opioid antagonist designed to provide analgesia while reducing abuse potential.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ALKS 9072 TARGET ALKS 9072 Alkermes, Inc. phase 3 Abuse-deterrent opioid analgesic Mu opioid receptor (with opioid antagonist component)
ALKS 9072, High ALKS 9072, High Alkermes, Inc. phase 3 Abuse-deterrent opioid analgesic Mu opioid receptor (with opioid antagonist component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Abuse-deterrent opioid analgesic class)

  1. Alkermes, Inc. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ALKS 9072 — Competitive Intelligence Brief. https://druglandscape.com/ci/alks-9072. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: